Organization
University Hospital Münster
3 abstracts
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.Org: IRCCS Humanitas Research Hospital, Rozzano, Italy, Humanitas University, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki University Hospital Comprehensive Cancer Center, Semmelweis University,
Abstract
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.Org: City of Hope National Medical Center, Genentech, BC Cancer Centre for Lymphoid Cancer, Centre Henri-Becquerel and University of Rouen, University Hospital Münster,